Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open‐label study-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open‐label study

Published:2024-03 Issue:3 Volume:14 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Wang Zhichao¹,Zhang Xin²,Li Chunyan³,Liu Yangbo³,Ge Xiaoyun³,Zhao Jiajia³,Yuan Xiaojun²,Li Qingfeng¹^ORCID

Affiliation:

1. Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medicine Shanghai China

2. Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine Shanghai China

3. AstraZeneca Global R&D (China) Co. Ltd. Shanghai China

Funder

Alexion Pharmaceuticals

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.1589

Reference10 articles.

1. The NF1 gene revisited - from bench to bedside

2. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis

3. Selumetinib in Children with Inoperable Plexiform Neurofibromas

4. U.S. Food and Drug Administration.Selumetinib (Koselugo) Full Prescribing Information. Accessed January 5 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas;Cancer Letters;2024-09

2. Targeting the extracellular matrix for NF1-associated neurofibroma treatment;Chinese Journal of Plastic and Reconstructive Surgery;2024-06